Salas-Humara Caroline, Sequeira Gina M, Rossi Wilma, Dhar Cherie Priya
NYU School of Medicine, Department of Pediatrics, Division of Adolescent Medicine, New York, NY, United States.
UPMC Children's Hospital of Pittsburgh, Center for Adolescent and Young Adult Health, United States.
Curr Probl Pediatr Adolesc Health Care. 2019 Sep;49(9):100683. doi: 10.1016/j.cppeds.2019.100683. Epub 2019 Nov 15.
The number of gender diverse and transgender youth presenting for treatment are increasing. This is a vulnerable population with unique medical needs; it is essential that all pediatricians attain an adequate level of knowledge and comfort caring for these youth so that their health outcomes may be improved. There are several organizations which provide clinical practice guidelines for the treatment of transgender youth including the WPATH and the Endocrine Society and they recommend that certain eligibility criteria should be met prior to initiation of gender affirming hormones. Medical intervention for transgender youth can be broken down into stages based on pubertal development: pre-pubertal, pubertal and post-pubertal. Pre-pubertally no medical intervention is recommended. Once puberty has commenced, youth are eligible for puberty blockers; and post-pubertally, youth are eligible for feminizing and masculinizing hormone regimens. Treatment with gonadotropin releasing hormone agonists are used to block puberty. Their function is many-fold: to pause puberty so that the youth may explore their gender identity, to delay the development of (irreversible) secondary sex characteristics, and to obviate the need for future gender affirmation surgeries. Masculinizing hormone regimens consists of testosterone and feminizing hormone regimens consist of both estradiol as well as spironolactone. In short term studies gender affirming hormone treatment with both estradiol and testosterone has been found to be safe and improve mental health and quality of life outcomes; additional long term studies are needed to further elucidate the implications of gender affirming hormones on physical and mental health in transgender patients. There are a variety of surgeries that transgender individuals may desire in order to affirm their gender identity; it is important for providers to understand that desire for medical interventions is variable among persons and that a discussion about individual desires for surgical options is recommended.
寻求治疗的性别多样化及跨性别青少年的数量正在增加。这是一个有着独特医疗需求的弱势群体;所有儿科医生都必须掌握足够的知识并安心为这些青少年提供护理,以便改善他们的健康状况。有几个组织提供了针对跨性别青少年治疗的临床实践指南,包括世界专业跨性别健康协会(WPATH)和美国内分泌学会,他们建议在开始使用性别肯定激素之前应满足某些资格标准。针对跨性别青少年的医学干预可根据青春期发育分为几个阶段:青春期前、青春期和青春期后。青春期前不建议进行医学干预。一旦青春期开始,青少年就有资格使用青春期阻滞剂;青春期后,青少年有资格使用女性化和男性化激素疗法。促性腺激素释放激素激动剂用于阻断青春期。其作用是多方面的:暂停青春期,以便青少年可以探索自己的性别认同;延迟(不可逆的)第二性征的发育;避免未来进行性别肯定手术的必要性。男性化激素疗法包括睾酮,女性化激素疗法包括雌二醇和螺内酯。在短期研究中,已发现使用雌二醇和睾酮进行性别肯定激素治疗是安全的,并能改善心理健康和生活质量;还需要更多长期研究来进一步阐明性别肯定激素对跨性别患者身心健康的影响。跨性别者可能希望通过各种手术来确认自己的性别认同;医疗服务提供者必须明白,不同人对医疗干预的需求各不相同,建议就个人对手术选择的需求进行讨论。